Akebia Therapeutics reported Q1 2026 net product revenues of $52 million, driven by a 60% increase in patients treated with Vafseo (vadadustat), which generated $15.8 million in revenue. Despite higher revenues from Vafseo, overall revenues declined slightly due to lower sales of Auryxia, leading to a net loss of $9.1 million compared to a net income in Q1 2025. The company is advancing its kidney disease pipeline with ongoing Phase 2 trials for praliciguat in FSGS and plans to start a Phase 2 basket study for AKB-097 in rare kidney diseases later in 2026. Akebia expects topline data from key Vafseo trials in late 2026 and early 2027, aiming to establish Vafseo as a standard treatment for anemia in dialysis patients.
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...
